NASDAQ: HEPAHepion Pharmaceuticals Inc Stock
$0.29+0.00 (+0%)
Updated Apr 30, 2025
HEPA Price
$0.29
Fair Value Price
N/A
Market Cap
$3.17M
52 Week Low
$0.25
52 Week High
$79.50
P/E
0x
P/B
-1.7x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.19M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.87
Operating Cash Flow
-$18M
Beta
1.03
Next Earnings
May 19, 2025
Ex-Dividend
N/A
Next Dividend
N/A
HEPA Overview
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HEPA's potential to beat the market
- HEPA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HEPA
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important HEPA news, forecast changes, insider trades & much more!
HEPA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HEPA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HEPA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HEPA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
HEPA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more HEPA due diligence checks available for Premium users.
Valuation
HEPA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-162.28x
Market
29.18x
HEPA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.7x
Industry
4.45x
HEPA's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.5M
Profit Margin
0%
HEPA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.6M
Liabilities
$3.5M
Debt to equity
-1.87
HEPA's short-term liabilities ($3.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HEPA's short-term assets ($1.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HEPA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HEPA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
$0.0
Financing
$0.0
HEPA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HEPA vs Biotech Stocks
Hepion Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.